Phase 1 3 Clinical Trials Expert Witnesses
Phase 1 3 clinical trials expert witnesses and consultants listed here may be able to form expert opinions, draft expert witness reports, provide expert witness testimony at deposition and/or trial as or serve as consulting (non-testifying) experts on phase 1 3 clinical trials. The phase 1 3 clinical trials expert witness listings on this page are typically from fields/areas of expertise such as: Hematology, Oncology, and Pharmaceutical Research.
Glen J Weiss, MD, MBA
Expert Witness: Oncology and Patent Litigation
MiRanostics Consulting, LLC
Boston, Massachusetts
Oncology, Hematology
-
Medical Oncology, Oncology Drug Development, Hematologic Malignancies, Medical Malpractice, Failure to diagnose cancer, Phase 1-3 Clinical Trials, Immunotherapy, Chemotherapy, Antibodies, Small Molecules, Targeted Therapy, Patent infringement, Indefiniteness, Improper cancer treatment
I am a board-certified medical oncologist with nearly 20 years of experience as a clinical investigator and translational researcher. I bring a deep understanding of oncology drug development and clinical practice. My leadership roles over the past 15 years span community, academic, and research institutions, including serving as faculty at Harvard Medical School. Currently, I am an Affiliate Associate Professor at UMass Chan Medical School and have over five years of experience as a biotech/pharmaceutical medical oncologist.
My industry roles include:
- Chief Medical Officer for a clinical-stage ADC company.
- Chief Medical Officer for a medical technology company developing AI-powered cancer diagnostic tools.
- Vice President of Clinical Sciences and medical lead for a CAR-T therapy development company.
In these positions, I contributed to business due diligence, investor fundraising presentations, and strategic clinical trial planning. As a clinical investigator, I ha...
Frederick H Hausheer, MD, FACP
Oncology Drug R & D, ICH GCP, Drug Patent Validity
HAUSHEER BIOMED, LLC USA
Austin, Texas
Oncology, Pharmaceutical Research
-
Oncology Drug Development, Patent Validity, ICH GCP, Written description, Enablement, Obviousness, Anticipation, Pharmacology, FDA, EMA, NMPA/China, PMDA/Japan, Drug formulation, Medical Safety, Phase 1-3 Clinical Trials, Drug Product Safety/Compliance, Medical Oncology
Dr. Frederick (Fred) Hausheer is a physician-scientist with over 37 years of executive leadership and management experience in US and international (EU, JP, China, others) commercial pharmaceutical research and development (Phase I-III), preclinical translational and clinical medicine, clinical pharmacology, ICH GCP compliance and commercial development strategy and risk management of novel cancer therapeutics. His commercial research and development experience includes cytotoxic agents, targeted agents, immuno-oncology therapeutics, cell therapies (BMT, CAR-T), and supportive care medicines. He is an inventor/co-inventor on more than 400 issued United States and international pharmaceutical patents, and author/co-author of more than 200 scientific/medical publications.
He is an experienced former CEO and Chief Medical Officer with several biopharma companies and a former NCI-Designated Clinical Investigator, NCI-Institutional Review Board voting member, and NCI-Experimental Ther...
